Company Description
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025.
Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 92 |
| CEO | Scott Plesha |
Contact Details
Address: 4020 Stirrup Creek Drive, Suite 110 Durham, North Carolina 27703 United States | |
| Phone | 919 908 2400 |
| Website | pelthos.com |
Stock Details
| Ticker Symbol | PTHS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001919246 |
| ISIN Number | US1711262048 |
| Employer ID | 86-3335449 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Scott M. Plesha | Chief Executive Officer, President and Director |
| Sai Rangarao M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2026 | 8-K | Current Report |
| Apr 10, 2026 | 8-K | Current Report |
| Mar 19, 2026 | 8-K | Current Report |
| Mar 19, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | 424B3 | Prospectus |
| Feb 9, 2026 | EFFECT | Notice of Effectiveness |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Feb 2, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 13, 2026 | 8-K | Current Report |